Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Convertible Debt (2016 - 2025)

Historic Convertible Debt for Coherus Oncology (CHRS) over the last 10 years, with Q1 2025 value amounting to $228.6 million.

  • Coherus Oncology's Convertible Debt rose 59.37% to $228.6 million in Q1 2025 from the same period last year, while for Mar 2025 it was $228.6 million, marking a year-over-year increase of 59.37%. This contributed to the annual value of $228.2 million for FY2024, which is 59.1% up from last year.
  • Coherus Oncology's Convertible Debt amounted to $228.6 million in Q1 2025, which was up 59.37% from $228.2 million recorded in Q4 2024.
  • In the past 5 years, Coherus Oncology's Convertible Debt ranged from a high of $332.8 million in Q4 2021 and a low of $223.3 million during Q1 2021
  • Moreover, its 5-year median value for Convertible Debt was $226.2 million (2023), whereas its average is $232.3 million.
  • Per our database at Business Quant, Coherus Oncology's Convertible Debt surged by 18319.05% in 2021 and then plummeted by 3221.23% in 2022.
  • Over the past 5 years, Coherus Oncology's Convertible Debt (Quarter) stood at $332.8 million in 2021, then crashed by 32.21% to $225.6 million in 2022, then increased by 0.58% to $226.9 million in 2023, then rose by 0.59% to $228.2 million in 2024, then grew by 0.15% to $228.6 million in 2025.
  • Its Convertible Debt stands at $228.6 million for Q1 2025, versus $228.2 million for Q4 2024 and $227.9 million for Q3 2024.